
Juliana Perez Botero

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4155204/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Apixaban and dalteparin in active malignancyâ€associated venous thromboembolism: The ADAM VTE trial. Journal of Thrombosis and Haemostasis, 2020, 18, 411-421.	3.8	381
2	Glanzmann thrombasthenia: genetic basis and clinical correlates. Haematologica, 2020, 105, 888-894.	3.5	75
3	The Society for Obstetric Anesthesia and Perinatology Interdisciplinary Consensus Statement on Neuraxial Procedures in Obstetric Patients With Thrombocytopenia. Anesthesia and Analgesia, 2021, 132, 1531-1544.	2.2	64
4	Apixaban and dalteparin in active malignancy associated venous thromboembolism. Thrombosis and Haemostasis, 2017, 117, 1952-1961.	3.4	62
5	Thrombotic Microangiopathy Care Pathway: A Consensus Statement for the Mayo Clinic Complement Alternative Pathway-Thrombotic Microangiopathy (CAP-TMA) Disease-Oriented Group. Mayo Clinic Proceedings, 2016, 91, 1189-1211.	3.0	55
6	Incidence of symptomatic venous thromboembolism in patients with hemophilia undergoing joint replacement surgery: A retrospective study. Thrombosis Research, 2015, 135, 109-113.	1.7	36
7	ASXL1 mutated chronic myelomonocytic leukemia in a patient with familial thrombocytopenia secondary to germline mutation in ANKRD26. Blood Cancer Journal, 2015, 5, e315-e315.	6.2	31
8	GoldVariants, a resource for sharing rare genetic variants detected in bleeding, thrombotic, and platelet disorders: Communication from the ISTH SSC Subcommittee on Genomics in Thrombosis and Hemostasis. Journal of Thrombosis and Haemostasis, 2021, 19, 2612-2617.	3.8	21
9	Clinical and laboratory characteristics in congenitalANKRD26mutation-associated thrombocytopenia: A detailed phenotypic study of a family. Platelets, 2016, 27, 712-715.	2.3	19
10	Specifications of the variant curation guidelines for <i>ITGA2B</i> / <i>ITGB3</i> : ClinGen Platelet Disorder Variant Curation Panel. Blood Advances, 2021, 5, 414-431.	5.2	19
11	Comprehensive Platelet Phenotypic Laboratory Testing and Bleeding History Scoring for Diagnosis of Suspected Hereditary Platelet Disorders. American Journal of Clinical Pathology, 2017, 148, 23-32.	0.7	16
12	Severe thrombocytopenia and microangiopathic hemolytic anemia in pregnancy: A guide for the consulting hematologist. American Journal of Hematology, 2021, 96, 1655-1665.	4.1	16
13	Successful treatment with thalidomide of a patient with congenital factor V deficiency and factor V inhibitor with recurrent gastrointestinal bleeding from small bowel arteriovenous malformations. Haemophilia, 2013, 19, e59-61.	2.1	15
14	Refractory bleeding from intestinal angiodysplasias successfully treated with danazol in three patients with von Willebrand disease. Blood Coagulation and Fibrinolysis, 2013, 24, 884-886.	1.0	14
15	Coagulation abnormalities and haemostatic surgical outcomes in 142 patients with Noonan syndrome. Haemophilia, 2017, 23, e237-e240.	2.1	12
16	Clinical characteristics and platelet phenotype in a family with <i>RUNX1</i> mutated thrombocytopenia. Leukemia and Lymphoma, 2017, 58, 1963-1967.	1.3	10
17	Do incident and recurrent venous thromboembolism risks truly differ between heterozygous and homozygous Factor V Leiden carriers? A retrospective cohort study. European Journal of Internal Medicine, 2016, 30, 77-81.	2.2	8
18	A proof-of-concept trial of protein kinase C iota inhibition with auranofin for the paclitaxel-induced acute pain syndrome. Supportive Care in Cancer, 2017, 25, 833-838.	2.2	7

Juliana Perez Botero

#	Article	IF	CITATIONS
19	Diagnostic Testing Approaches for Activated Protein C Resistance and Factor V Leiden. American Journal of Clinical Pathology, 2017, 147, 604-610.	0.7	7
20	Hermansky-Pudlak syndrome subtype 5 (HPS-5) novel mutation in a 65 year-old with oculocutaneous hypopigmentation and mild bleeding diathesis: The importance of recognizing a subtle phenotype. Platelets, 2018, 29, 91-94.	2.3	7
21	Congenital Disorders of Platelet Function and Number. Pediatric Clinics of North America, 2018, 65, 561-578.	1.8	7
22	ANKRD26-Related Thrombocytopenia and Predisposition to Myeloid Neoplasms. Current Hematologic Malignancy Reports, 2022, 17, 105-112.	2.3	7
23	Grey platelet syndrome misdiagnosed as <scp>ITP</scp> . British Journal of Haematology, 2016, 173, 662-662.	2.5	5
24	Gray Platelet Syndrome Presenting With Pancytopenia, Splenomegaly, and Bone Marrow Fibrosis. American Journal of Clinical Pathology, 2021, 156, 253-258.	0.7	5
25	Diagnostic approach to the patient with a suspected inherited platelet disorder: Who and how to test. Journal of Thrombosis and Haemostasis, 2021, 19, 2127-2136.	3.8	5
26	Delayed diagnosis of MYH-9–related disorder and the role of light microscopy in congenital macrothrombocytopenias. Blood, 2016, 127, 1940-1940.	1.4	4
27	Primary Lymphedema and Viral Warts in GATA2 Haploinsufficiency. Mayo Clinic Proceedings, 2017, 92, 482.	3.0	4
28	Practice patterns in the diagnosis of inherited platelet disorders within a single institution. Blood Coagulation and Fibrinolysis, 2017, 28, 303-308.	1.0	4
29	von Willebrand disease type1/type 2N compound heterozygotes: diagnostic and management challenges. British Journal of Haematology, 2017, 176, 994-997.	2.5	4
30	Clinical spectrum and clonal evolution in germline syndromes with predisposition to myeloid neoplasms. British Journal of Haematology, 2018, 182, 141-145.	2.5	4
31	Phenotypic heterogeneity associated with germline <i>GATA2</i> haploinsufficiency: a comprehensive kindred study. Leukemia and Lymphoma, 2019, 60, 3282-3286.	1.3	4
32	Novel Genetic Variants in Complement-Mediated Thrombotic Microangiopath. Blood, 2015, 126, 1050-1050.	1.4	3
33	Single Antigen Bead Results Complement Platelet Crossmatch in Selecting Platelet Units Leading to Adequate Transfusion Yield in Refractory Patients. Blood, 2016, 128, 1459-1459.	1.4	3
34	Spur cell anemia in the setting of progressive liver allograft failure. American Journal of Hematology, 2016, 91, 1061-1061.	4.1	2
35	Factor IX Gene (F9) Genotyping Trends and Spectrum of Mutations Identified: A Reference Laboratory Experience. Seminars in Thrombosis and Hemostasis, 2018, 44, 287-292.	2.7	2
36	Recognition of the unique bleeding pattern and laboratory findings in acquired haemophilia A facilitates prompt treatment of a life-threatening disorder. BMJ Case Reports, 2021, 14, e244238.	0.5	1

Juliana Perez Botero

#	Article	IF	CITATIONS
37	Value of Platelet Esoteric Testing in Laboratory Diagnosis of Platelet Disorders: A Single Center Experience. Blood, 2015, 126, 1061-1061.	1.4	1
38	Fanconi Anemia—Protean Manifestations of Defective DNA Repair. Mayo Clinic Proceedings, 2016, 91, 824-825.	3.0	0
39	The Impact of Antithrombin Deficiency on Women's Reproductive Health Experiences and Healthcare Decision-Making. Journal of Women's Health, 2017, 26, 1350-1355.	3.3	0
40	Incidence Of Symptomatic Venous Thromboembolism In Patients With Hemophilia Undergoing Joint Replacement Surgery: A Retrospective Study. Blood, 2013, 122, 2348-2348.	1.4	0
41	Prevalence of Venous and Arterial Thrombosis Among 268 Heterozygous and 111 Homozygous Factor V Leiden Carriers: a Single-Center Cross-Sectional Study. Blood, 2014, 124, 1536-1536.	1.4	0
42	Platelet Transmission Electron Microscopy and Flow Cytometry in the Diagnosis of Congenital/Hereditary Qualitative or Quantitative Platelet Disorders. Blood, 2015, 126, 3476-3476.	1.4	0
43	Clinical Spectrum of Germline Mutations with Predisposition to Myeloid Neoplasms- 2016 World Health Organization Classification Update. Blood, 2016, 128, 300-300.	1.4	0
44	Coagulation Abnormalities and Hemostatic Surgical Outcomes in 142 Patients with Noonan Syndrome. Blood, 2016, 128, 1417-1417.	1.4	0
45	The Impact of Antithrombin Deficiency on Women's Reproductive Health Experiences and Healthcare Decision-Making: A Qualitative Patient-Oriented Survey Study. Blood, 2016, 128, 3588-3588.	1.4	Ο